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Abstract: The production of an intramuscular (IM) injection of natural progesterone would 
provide a safer solution than using semi synthetic progesterone. However, disadvantages such 
as low solubility and a short half life prevent the use of natural progesterone. In this study, we 
formulated a sustained release form of natural progesterone to be given as IM injection. A pro-
gesterone nanosuspension (PNS) was first developed and then dispersed in a thermosensitive gel 
matrix. The selected nanoparticles showed an average particle size of 267 nm and a zeta potential 
approaching-41 mV. The in vitro release profile of PNS from the F127 plus methyl cellulose gel 
followed zero order kinetics and correlated linearly with the weight percentage of gel dissolved, 
demonstrating that the overall rate of release of PNS is controlled by dissolution of the pluronic 
F127/methyl cellulose (MC) gel (r2 . 0.99). The pharmacokinetic parameters of the PNS (6 mg/mL) 
in pluronic F127/MC gel were evaluated in comparison with the control progesterone suspension. 
After the administration of PNS in F127/MC gel into the rats, a maximum serum concentration of 
22.1 ± 1.9 ng/mL was reached at a Tmax of 4.05 ± 0.1 h. The terminal half life was 12.7 ± 0.8 h. The 
area under the curve AUC0-∞ of the injected formula was 452.75 ± 42.8 ng·h/mL and the total mean 
residence time was 18.57 ± 1.44 h. The PNS in gel was significantly different from the control in 
rate and extent at P , 0.001. The natural progesterone which was nanosized and formulated in a 
thermosensitive gel significantly sustained the action of natural progesterone so that it could be 
injected every 36 h instead of every day. Moreover, this formula is expected to provide a much 
safer choice than the use of semi-synthetic progesterone.
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Introduction
Since the 1950s, a variety of gynecological conditions have been either corrected or 
treated using oral synthetic progesterone. However, the androgenic activity inherent 
in these synthetic compounds minimizes its extensive use in reproductive technology 
because of the risk of teratogenic effects. Furthermore, the use of synthetic progester-
one as a luteal support may partially diminish the estrogenic benefits due to adverse 
effects on the cardiovascular system and lipoprotein metabolism.1–3
Natural progesterone is free of any androgenic activity that might affect lipoprotein 
metabolism or induce teratogenicity. In addition, it probably has a beneficial effect on 
blood vessels.4 The major problem with natural progesterone is its route of adminis-
tration since it is a hydrophobic drug which undergoes a first pass effect by the liver 
when it is given orally.2,5,6
An intramuscular (IM) injection of progesterone assures reliable absorption, 
but it has a low compliance due to the use of oil as a vehicle. Although, it is highly International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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  successful in achieving high serum levels of progesterone, 
the daily injection of progesterone for up to 10 weeks (in 
case of using it as luteal support if pregnancy occurs) leads 
to pain and local inflammatory actions and may lead to sterile 
abscesses.6,7 Hydrophilic vehicles are preferable to using oil. 
However, their use as carriers is mainly confined to hydro-
philic drugs. Hydrophobic drugs such as progesterone need 
size reduction and surface modifications for a uniform distri-
bution within hydrophilic vehicles. However,   nanonization 
and surface modifications can both provide a uniform distri-
bution of hydrophobic drugs within hydrophilic gels.
Many drugs are formulated as a nanosuspension, such as 
cyclosporine,8 griseofulvin,9 retinoic acid,10 albendazole,11 
amphotericin B,12 budesonide,13 clofazamine,14 glucocorti-
coid drugs,15 mitotane,16 and nifedipine.17
There are two main methods of producing nanosuspen-
sions: the first one is via the solvent precipitation technique,10 
the other one is via high pressure homogenization.14 The 
precipitation technique is preferred in many situations due 
to its low cost and high efficiency. The drug is dissolved 
in an organic solvent and the solution is then mixed with 
a miscible antisolvent. Water is usually used as an antisol-
vent in cases where the solubility of a drug is low and the 
drug precipitates easily.9,10,16 The stability of the particles 
obtained in the nanosuspension is attributed to their uniform 
particle size and due to the stabilization of their surfaces by 
amphiphilic surfactants.18
The use of hydrophilic matrices (polymers) is a com-
mon practice for elongating the release of drugs as they are 
proven to be safe and effective. Pluronics have been cited 
in the literature as being used as hydrophilic thermosensi-
tive polymers for sustaining the action of many hydrophilic 
drugs given by injection, such as interleukin-2,19 recombinant 
human growth hormone,20 and deslorelin.21
Pluronics are a family of commercially available block 
copolymers with variable surface properties. Pluronic F127, 
also known as poloxamer 407, is an ABA block copolymer 
formed of poly(oxyethylene) units (70%) referred to as A and 
poly(oxypropylene) blocks (30%) referred to as B,22 which 
undergo a thermogelation phenomenon upon increasing 
temperatures. This phenomenon is responsible for elongating 
the release of drugs.21
The aim of this work was to engineer a sustained-release 
thermosensitive injection of a progesterone nanosuspension 
(PNS) stabilized by amphiphilic moieties. The amphiphilic 
moiety (stearic acid) was used to facilitate the dispersion 
of the nanosuspension in the hydrophilic matrices.18 This 
formula could later be used as a luteal supporting agent 
in oocyte retrieval. The second aim of the study was to 
compare the in vivo performance of the chosen formula 
with an equivalent dose of natural progesterone powder in 
ovariectomized female rats.
Materials and methods
Materials
Pluronic F127, progesterone powder C21H30O2 (4-pregene-3,20-
dione), stearic acid, methyl cellulose (MC) with a viscosity 
of 400 centiPoises (cP), hydroxy propyl methyl cellulose 
(HPMC) with a viscosity of 80–120 cP, phosphate-buffered 
saline (PBS) tablets containing NaCl (0.1 N), and phos-
phate buffer (0.01 M, pH 7.4) were all purchased from 
Sigma Aldrich (Cairo, Egypt). Absolute ethanol (95% v/v) 
was provided by Thermo Fisher’s analytical technologies 
segment (Thermo Fisher Scientific Inc., Cairo, Egypt). The 
ELISA kit for progesterone detection was purchased from 
BioTina GmbH (Hagen, Germany).
Preparation of PNS
Preparation of the nanoparticles was carried out using the 
solvent precipitation method with modifications.18 In brief, 
nanoparticles were prepared by the rapid mixing of progester-
one (200 mg) with different amounts of stearic acid powder 
(5%, 10%, and 20% w/w) in ethanol (1 mL). This solution 
was added to 60 mL of cold deionized water using syringe 
dropping under probe sonication (model GM 2200; Bandolin 
Electronic, Berlin, Germany) at 60% amplitude for 20 s. The 
resulting colloid was then frozen at −20°C and freeze dried. 
A small volume of the colloid (1 mL) was kept back from 
lyophilization for the purpose of imaging and particle size 
measurement.
The yield was calculated using the following equation 
(Eq. (1)):
  Yield = Masspowder / Massinitial × 100  (1)
Particle size analysis
The z-average particle sizes and polydispersity index were 
determined using the PCS4700 system (Malvern Instruments, 
Malvern, UK), while the zeta potential of the nanosuspension 
samples was determined using the Zetasizer 2000 (Malvern 
Instruments).
Differential scanning calorimetry
Progesterone powder, stearic acid, or PNS (4 mg) were sealed 
in the flat-bottomed aluminum pan of the differential scanning 
calorimetry (DSC) (DSC-50; Shimadzu Corporation, Kyoto, International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Japan). A standard empty pan was inserted along with each 
pan to account for the heating of pure aluminum. The sample 
and the blank were continuously purged with nitrogen gas 
at a flow rate of 25 mL/min. Data collection was carried out 
at the temperature range of 20°C to 200°C and the heating 
rate was 5°C/min. The melting and transition point measure-
ments were performed using the software provided with the 
device.
Scanning electron microscopy
The PNS in PBS was mounted onto cupper stubs with double-
sided adhesive tape and coated with gold using a Sputter 
Coater (S150A; Edwards High Vacuum Ltd, Crawley, UK). 
The sample was examined under a JXA-840 A electron probe 
microanalyzer (JEOL Ltd., Akishima, Japan).
In vitro release study  
of the nanosuspensions
Six milligrams of the post-treated solid residues in the previ-
ous section were re-dispersed in 2 mL of PBS (pH 7.4) and 
then transferred to a dialysis bag (molecular weight cut-off 
4 kDa). These bags were hung in a covered beaker containing 
the dissolution medium (60 mL). The dissolution medium 
was stirred at 200 rpm at room temperature. The drug con-
tents were determined using an ELISA kit (BioTina GmbH) 
at different time intervals. As a comparison, the diffusion 
profile of the pure drug dispersion was examined through 
the dialysis bag. The pure drug dispersion was prepared by 
dispersing an equivalent amount of progesterone powder in 
2 mL of PBS. Each releasing experiment was performed in 
triplicate.18
Preparation of pluronic  
thermosensitive gel bases
One milliliter of isotonic PBS (0.1 M, pH7.4) was used in 
each base preparation. Appropriate amounts of pluronic F127 
were used alone or premixed with either MC (1% w/v) or 
HPMC (1% w/v) to modify the rate at which the pluronic 
gels dissolved (Table 1). The final concentrations of pluronic 
F127 were 17% w/v, 25% w/v, and 30% w/v, respectively. 
The weights of the nine bases were kept constant by adding 
a sufficient amount of buffer. The mixtures were vortexed 
and kept in the fridge for 24 h before use. For preparation of 
the pluronic bases to carry the progesterone nanoparticles, 
the nanoparticles were first premixed with pluronic F127 
with or without the above additives before being mixed with 
different volumes of PBS to keep the final volume constant 
in all preparations. The final concentrations of progesterone 
were 6 mg/mL in all preparations.
characterization of the  
thermosensitive bases
gelling point determination and rheological 
characterization of the thermosensitive bases
The inverted test-tube method was used to determine the 
gelling point of the bases. One milliliter of each base, either 
with or without the nanoparticles, was put in a water bath with 
temperature increasing from 4–60°C. The sol-gel transition 
temperature was assessed. The base is regarded as “gel” if it 
could not flow down the test tube when it was inverted.
The nine bases were tested for their viscosity in the pres-
ence or in the absence of progesterone nanoparticles (6 mg) 
using a Brookfield viscometer (DV-III programmable Rhe-
ometer; Brookfield Engineering LABS, Stoughton, MA). The 
measurements were carried out over the entire range of speed 
setting from 1–200 rpm with 60 s between each successive 
points with the temperature controlled at 4°C.
The cumulative percentage weight of dissolved  
gel (matrix erosion or weight loss)
The nine pluronic bases were placed into a thermostatically-
controlled water bath (Aditi Associate, Mumbai, India) 
maintained at 37°C for 8 h. The difference in weights of the 
vials with and without the bases gave the initial weight of 
the pluronic bases used, while the difference in weight of the 
pluronic bases at two adjacent points after addition of the 
buffer represented the amount of dissolved gel.
In vitro release studies  
of the PNS from the gel
An in vitro release study of the PNS from the F127 gel was 
performed using a membrane less dissolution model.21 One 
milliliter of the different pluronic bases alone or with either 
HPMC or MC was placed into 3 mL vials. The vials were 
placed into the shaking water bath, which was maintained at 
37°C. After the drug bases had transformed into a gel form, 
the PBS solution (1 mL, pH 7.4) was carefully layered over 
Table 1 composition of different thermosensitive bases. B re-
presents the base number.  All bases contain the same amount of 
progesterone (6 mg/mL)
The additives Pluronic 
(17% w/v)
Pluronic 
(25% w/v)
Pluronic 
(30% w/v)
None B1a B4 B7
hPMc (1% w/v) B2 B5 B8
Mc (1% w/v) B3 B6 B9International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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the surface of the gel. At predetermined time intervals, the 
entire release medium was removed, the vial was weighed 
and fresh medium was replaced. The samples were analyzed 
for progesterone using an ELISA microplate autoreader 
(Model EL-311; Bio-Tek Vermont, CA) according to the 
manufacturer’s instructions (BioTina GmbH).
Preparation of animals
Twelve adult female Sprague-Dawley rats with an average 
weight of 250–300 g were provided by the animal house of 
the National Organization of Drug Control and Research, 
Egypt. All of the animals were handled humanely according 
to the Helsinki protocols. Before the experiment, the rats 
were humanely ovariectomized according to the method 
of Flores et al.23 Briefly, the rats were anesthetized and the 
lower abdomen was shaved and incised. Both ovaries were 
removed and then the ovariectomized rats were kept for 
two weeks after the operations before injecting them with 
a progesterone base. The doses were calculated according 
to Paget and Barners24 to be equivalent to doses used for 
humans.
Treatment and blood sampling
At the time of the experiment, the rats were divided into 
two groups; each group contained six female rats. The first 
group was injected with B6 (1000 µL) which was composed 
of progesterone (6 mg/mL), pluronic F127 of 25% w/v plus 
MC (1% w/v). The second set of rats was injected with 
natural progesterone suspended in PBS (6 mg/mL). All 
mixtures were IM injected into the lower limb of the rats. 
Blood samples (250 µL) were drawn at 0, 0.25, 0.5, 0.75, 1, 
2, 4, 6, 8, 24, and 36 h post administration. The plasma was 
separated and frozen. The plasma progesterone concentration 
was determined using a BioTek ELISA microplate autoreader 
(Model EL-311) according to the manufacturer’s instructions 
(BioTina GmbH). The mean levels of endogenous progester-
one in the investigated rats were assessed at 48 h before the 
experiment and found to be 0.36 ± 0.12 ng/mL. These values 
were used to correct the level of exogenous progesterone. 
Therefore, the level of endogenous progesterone of each rat 
was subtracted from the level of exogenous progesterone at 
each point on the area under curve to exclude the effect of 
any small fractions of endogenous progesterone.
Results and discussion
Natural progesterone is the most important drug used as a 
luteal support in oocyte retrieval. The importance of natural 
progesterone arises from its similarity to the progesterone 
naturally present in high concentrations in the body and 
therefore does not pose any toxicity problems, unlike syn-
thetic progesterone.25,26 Progesterone is not orally active 
except in high doses and has a very short biological half 
life, which makes it an ideal candidate for inclusion in a 
thermosensitive matrix which controls its deposition and 
sustains its action when given by the IM route of admin-
istration. Hydrophobicity, low solubility, and the large 
particle size of natural progesterone hinder its uniform 
distribution in hydrophilic thermosensitive polymers. 
Therefore, size reduction and surface stabilization by stearic 
acid is thought to provide uniform distribution within the 
hydrophilic matrix when examined under the microscope 
and also by eye.18
Preparation and characterization  
of the nanosuspensions
In this section of the study, sustained-release injections 
of natural PNS using stearic acid as the surface stabilizer 
were prepared. Stearic acid has amphiphilic characteristics 
as it is a solid at room temperature, and is thought to form 
a thin layer surrounding the drug nanodispersion. The 
amphiphilic nature of stearic acid makes it act as an interface 
between the progesterone nanoparticles and the hydrophilic 
medium. Stearic acid is presumed to be the provider of the 
negative charges on the surface of the hydrophobic proges-
terone (Table 2).18 All of the nanosuspension formulations 
showed a macroscopic homogenous appearance, which 
Table 2 Physicochemical properties of progesterone nanoparticles
Concentration 
of stearic acid
Parameters Value ± SD
Stearic acid (5% w/w) Zeta potential (mV) −23 ± 7
Mean particle size 
diameter (nm)
680 ± 60
Polydispersity index 
of the NP
0.36 ± 0.1
Yield 40%
Stearic acid (10% w/w) Zeta potential (mV) −37 ± 6
Mean particle size 
diameter (nm)
290 ± 20
Polydispersity index 
of the NP
0.24 ± 0.09
Yield 69%
Stearic acid (20% w/w) Zeta potential (mV) −41 ± 5
Mean particle size 
diameter (nm)
267 ± 10 
Polydispersity index 
of the NP
0.21 ± 0.02
Yield 82%
Abbreviation: SD, standard deviation.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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was milky white in color when examined by eye before 
lyophilization.
The amount of stearic acid added was found to have 
the main effect on the particle size produced. The particles 
with the smallest sizes were those produced with highest 
amount of stearic acid (Table 2). The yield also increased 
by increasing the concentration of stearic acid used, which 
may be due to the repulsion occurring between the nano-
particle surfaces and the walls of the glass vessels upon 
transfer. We presumed that the ratio between progesterone 
and stearic acid was still the same after lyophilization in 
each case.
It was also observed that nanoparticle size could be 
controlled by controlling the operating conditions during the 
formation of the colloid, such as the volume of the solvent/
antisolvent system (data not shown), because the percent-
age of the particle precipitation was strongly dependent on 
the relative solubility of the drug in both phases (solvent/
antisolvent). Other operating conditions were found to have 
effect on particle size, such as mixing energy and length of 
the mixing time (data not shown).
Sufficient mixing of these two phases, which was 
achieved via ultrasonication at low to moderate amplitudes, 
led to nucleation and growth kinetics and finally to the forma-
tion of submicron particle sizes.
Particle size analysis showed the presence of submicron 
structures with acceptable polydispersity indices (Table 2). 
The results were in agreement with the electron micrograph 
results. Scanning electron microscopy showed the formation 
of spherical and oblate shaped nanoparticles, somewhere 
below 500 nm in size. The size distribution was in accordance 
with other nanosuspension systems described in the litera-
ture.18 Sickle shaped nanoparticles were also seen and thought 
to be the aggregation of two or three oblate nanoparticles, all 
below 1 µm in size. The presence of these aggregates may 
have been the reason for the relatively high polydispersity 
indices (Figure 1).
DSC thermographs were used to investigate the presence 
of chemical interactions between progesterone and stearic 
acid which may affect the therapeutic effect of progesterone. 
Both progesterone and stearic acid exhibited sharp endother-
mic peaks when they underwent a melting phenomenon upon 
heating (Figure 2). The results showed a lack of interaction 
between the drug and stearic acid, which suggested the forma-
tion of physical mixture in the case of the nanosuspension. 
It was also found that the enthalpy of the nanoparticles was 
6000X 8 µm X8500 6 µm
3700 10 µm
Figure 1 SeM images for a) the progesterone nanosuspension after lyophilization; b) the progesterone nanosuspension sample before lyophilization; c) the progesterone 
powder as received.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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lower than that of the pure drug, which may be attributed to 
the presence of a small amount of stearic acid surrounding 
the progesterone without invading it; however, there was no 
clear evidence supporting this theory. The results showed 
an absence of a significant shift in the endothermic peak of 
the progesterone (the peak shifted from 131°C to 128°C), 
which is an indication of the lack of significant changes in 
the crystalline state of the progesterone and hence it is an 
indication of the presence of stearic acid on the surface, but 
not within the progesterone particles. The results of the DSC 
thermographs are summarized in Table 3.
The in vitro dissolution profile of the three nanoparticle 
series using progesterone powder as a control is shown 
in Figure 3a. The cumulative percentage of progesterone 
released from the nanoparticles formed by the addition of 
20%, 10%, and 5% of stearic acid at the end of 10 h was 
88 ± 5.4, 76 ± 8.2, and 60% ± 5.3%, respectively. A Higuchi 
plot (amount of PNS series released versus square root of 
time) indicated a linear release during the 10 h of the study 
(Figure 3b). This indicates that the overall rate of progester-
one release was controlled by diffusion of the drug from the 
nanosuspension. It also shows the importance of the stearic 
acid concentration in modulating the rate of release. By 
increasing the stearic acid concentration, a small amount 
of nanosuspension of progesterone was formed with low a 
polydispersity index, which indicates that the size distribu-
tion of the particles is homogenous. Therefore, Ostwald 
ripening is not likely to occur in this case. Ostwald ripening 
takes place if the particle size distribution is not homogenous 
or polydisperse. According to this theory, the dissolution 
pressure over the small particles with an increased degree 
of curvature of the surface is increased. Therefore, smaller 
particles dissolve and recrystallize on the surface of larger 
particles leading to an increase in the particle size and conse-
quently the dissolution rate is decreased due to the formation 
of large particles.27 The rate of dissolution was found to be 
in the following order: progesterone powder . progesterone 
with stearic acid (5%) . progesterone with stearic acid 
(10%) . progesterone with stearic acid (20%). Sink condi-
tions were maintained in this experiment by increasing the 
surface area of the drug used so the solubility was enhanced. 
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Table 3 DSc peak integrations for pure progesterone, pure stearic 
acid, and progesterone nanosuspension in lyophilized form
Sample Peak location (°C) Enthalpy (J/g)
Progesterone 131.0 58.8
Stearic acid 60.0 387
Nanosuspension 
progesterone peak
128.9 58
Stearic peak 55.6 9.8
Abbreviation: DSc, differential scanning calorimetry.
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Figure  3  In  vitro  release  of  progesterone  nanosuspension  and  progesterone 
powder. A) cumulative percentage drug release versus time; B) higuchi plot of the 
cumulative percentage amount of drug released versus the square root of time. 
Notes:  progesterone  powder  suspended  in  phosphate-buffered  saline  (), 
progesterone nanosuspension stabilized with 5% (w/w) stearic acid (), progesterone 
nanosuspension  stabilized  with  10%  (w/w)  stearic  acid  (),  and  progesterone 
nanosuspension stabilized with 20% ( w/w) stearic acid (). each point represents the 
mean of three replicates. error bars were omitted in some series for clarity. The in 
vitro release study was conducted at 25°c.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
949
Sustained-release PNS in ovariectomized rats
The saturated solubility of the nanosuspension containing 
stearic acid (20%) was assessed to be 295 µg/mL while the 
solubility of natural progesterone was 7 µg/mL. Stearic acid 
as an amphiphilic moiety might enhance the solubility of the 
drug by stabilizing the nanoparticles produced and by the 
formation of hydrogen bonds with water in the dissolution 
medium. It is necessary to have sink condition so that the 
release of drug is solely governed by the delivery system and 
not affected by the solubility factors.28
Therefore, increasing the concentration of stearic acid 
from 5% to 20% enhanced the physicochemical properties by 
forming smaller particles with a lower polydispersity index 
and with a zeta potential up to 41 mV (Table 2). The negative 
value of the zeta potential of the nanosuspensions linearly 
increased, reaching 41 mV in presence of 20% stearic acid. 
This value provided colloidal stability for the nanoparticles. 
In addition, it gave them a greater ability for distribution 
within hydrophilic bases. This value is also far from the 
agglomeration threshold defined by Riddick.29
The formula that included stearic acid (20%) was chosen 
to complete the study by including the nanosuspension in the 
pluronic thermosensitive bases. Different blends of pluronic 
F127 with HPMC and MC as additives were examined to 
determine which base was best able to elongate the release 
of the nanoparticles. Incorporation of hydrophilic polymers 
(HPMC) or the less hydrophilic additive MC into pharma-
ceutical formulations is common practice for retarding the 
release of drugs, thereby achieving a sustained drug deliv-
ery system. A set of experiments was conducted to choose 
the base most able to sustain the release of progesterone 
when administered via the IM route. In order to choose a 
limited number of bases able to deliver progesterone in a 
sustained release manner, we needed to know the optimum 
  concentration of polymer blends that was less prone to ero-
sion by the dissolution medium.
The nine bases used in this study existed as a free flow-
ing but viscous liquid at the storage temperature (4°C). The 
concentrations of the additives used in this study represent 
the highest concentration that kept the sol-gel characteristics 
of the F127 bases (data not shown). The F127 formulations 
which contained no additive were used as controls.
Characterization of the 
thermosensitive bases
gelling temperature and rheological properties  
of thermosensitive gels
Table 4 shows the sol-gel transition temperature of the nine 
bases in the presence or in the absence of PNS. No signifi-
cant difference was found between the gelling temperature 
of most bases either in the presence or in the absence of 
progesterone nanoparticles. Only B2 showed a significant 
difference between the gelling temperature of the bases in 
the presence and in the absence of the drug at P , 0.05. 
However, a remarkable decrease in the gelling temperature 
occurred with the increase in F127 concentrations. The 
same phenomenon (gelling temperature decrease) was 
recognized upon the addition either of HPMC or MC to the 
bases (Table 4).
Pluronics have thermoreversible behavior in aqueous 
solution. By increasing the temperature, they aggregate in 
micelles to minimize the free energy of the solution. How-
ever, at low temperature, pluronics exist as monomers in 
solution. Upon warming, the equilibrium between monomers 
and micelles is reached, and finally aggregates are formed 
at either higher temperatures or higher concentrations. 
These micelles are usually spherical in shape and consist 
Table 4 gelling temperature and viscosity of different F127 bases either in the presence or in the absence of progesterone (n = 4 ± SD)
Base 
No.
Gelling 
temperature 
(°C)a
Gelling 
temperature 
(°C)b
t-test Viscosity 
(cP)c
N Viscosity 
(cP)d
N
B1   29.8 ± 0.44   29.4 ± 0.54 P . 0.05 370  2.60 410 2.40
B2 48.75 ± 0.50 45.25 ± 0.50 P , 0.05  120 2.03 340 1.80
B3   25.5 ± 0.50 25.25 ± 0.50 P . 0.05 420 1.72 510 3.12
B4 23.25 ± 0.5   22.5 ± 1.9 P . 0.05 630 2.10 1120 2.12
B5        21 ± 0.80   20.8 ± 0.50 P . 0.05 430 2.43 340 2.22
B6        19 ± 0.80        19 ± 0.00 P . 0.05 794 2.82 945 3.01
B7        15 ± 0.50        13 ± 0.00 P . 0.05 1958 2.51 2880 3.58
B8        13 ± 0.00 10.25 ± 0.50 P . 0.05 2214 2.82 2987 3.07
B9   10.5 ± 0.50        10 ± 0.00 P . 0.05 2589 2.76 3306 2.1
Notes: N is a constant that represents the slope of log F against log g. agelling temperatures of bases in the absence of progesterone; bgelling temperatures of bases in the 
presence of progesterone; cViscosity of gel in the absence of progesterone at 4°c; dViscosity of gel in the presence of progesterone 4°c.
Abbreviations: cP, centipoises; SD, standard deviation.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of a   hydrophobic core of poly (oxypropylene) blocks and 
hydrophilic shell of polyethylene glycol.30,31
The decrease in the gelation temperature with the increase 
in F127 concentration may be attributed to the higher number 
of micelles that occupy the same volume of aqueous medium. 
When the concentration of F127 increases, the gel structure 
becomes more packed in a lattice pattern, which may lead to 
gelling temperature depression. However, the present study 
shows that PNS in a concentration of 6 mg/mL does not 
reduce the gelation temperature of F127 at all concentra-
tions. This phenomenon may be attributed to the hydrophobic 
nature of progesterone. Progesterone nanoparticles might 
be localized within the micelles core so they did not affect 
water content of the gel, micellar aggregation, or the gelling 
temperature.32 It is clear that all the bases except B2 will be 
able to congeal inside the body at physiological temperature. 
In most of the studied bases, the gelation temperature is far 
below the body temperature. This difference is a sign for 
the in situ congealing of the gel within the body. If the dif-
ference between gelling point of the gel and physiological 
temperature is small, the in situ congealing of the gel cannot 
be assured and a burst in the drug release may occur. The 
drug can diffuse out of the nonsolidified gel more rapidly 
and the burst can occur.33
Table 4 shows the values of the viscosity coefficient of the 
nine bases at 4°C as well. The flow behavior of the different 
gel bases was studied according to equation (2):
  Log G = N Log F – Log η  (2)
where F is the shear rate in sec-1; G is the shear stress in 
dyne/cm2, η is the viscosity coefficient in cP and calculated 
from the intercept of log F against log G, while N is the slope 
of the plot. When N is less than 1, dilatant flow is attained, 
and if it is greater than 1, pseudoplastic flow is achieved.34
F127 bases can be administered in liquid form at 4°C.34–36 
When converted to semisolid gels at body temperature, they 
act as sustained release depots (1). All of the investigated 
bases show a sheer thinning behavior and pseudoplastic 
flow which can be determined from the slope of the plot 
above 1.34 The viscosity coefficient is usually increased by 
increasing the concentration of pluronics. Addition of pro-
gesterone nanoparticles did not affect the trend of the gel 
flow, ie, pseudoplasticity. The viscosity is a very important 
parameter because it has a direct relationship with syringe-
ability. In development of thermosensitive injectable gels, 
the syringe-ability is an important factor, influencing the 
ease of administration of the injectable gels to the body. 
The threshold of appropriate syringe-ability was reported by 
Xuan et al.37 Below this threshold, it is easy to administer 
the gel. For the gels containing poloxamer, the threshold in 
syringe-ability is a viscosity of about 300 mPa.s which is 
equivalent to 300 cP.37 In the present study not all the bases 
are below this threshold; however they do undergo a sheer 
thinning behavior when they are shaken in the bottle or dur-
ing injection by syringes.
The cumulative percentage weight of dissolved  
gel (matrix erosion or weight loss)
The cumulative percentage weight of dissolved gel experi-
ment (matrix erosion/weight lost) was carried out to study the 
correlation between the cumulative percentage weight loss 
of dissolved gel versus time (Figures 4a, 4b, 4c). The bases, 
which show high viscosity and rigidity at 37°C, are less prone 
to erosion and to weight loss than the less viscous ones.22 
Therefore, all of the bases with a pluronic gel concentration of 
17% w/v such as B1, B2, and B3 (Figure 4a) dissolved faster 
than the others, which have higher concentration of pluronic, 
ie, B4, B5, B6, B7, B8, and B9 (Figure 4b and 4c).
B1 dissolved after 6 h while B3 dissolved after 8 h. How-
ever, B2 (the base which contained 17% pluronic gel and 
HPMC) did not show any tendency to congeal at 37°C. This 
may be due to the presence of a fewer number of micelles 
per unit volume in B2, in addition to the extensive hydrating 
effect of HPMC in this base.22,30 This combined effect might 
be the main reason why the gel of B2 did not solidify under 
the conditions of the experiment.
In all of the studied bases, the cumulative amounts of gel 
dissolved versus time were in the order of pluronic . pluronic 
and HPMC . pluronic and MC, and there was a strong cor-
relation with time (r2 . 0.97). Addition of MC to the bases 
showed a linear correlation between the weight loss of the 
base versus different time intervals. This phenomenon may 
be attributed to the chemical structure of MC which is less 
hydrophilic than both pluronic and HPMC. Hydrophilic bases 
tend to keep water in their micellar aqueous channels which 
may lead to the increase in the percentage of gel dissolved 
versus time. Four bases that exhibited slower gel dissolutions 
were selected for further in vitro release studies with 25% 
pluronic gel w/v as a control.
The cumulative release of the drug  
from the thermosensitive matrix
The effect of the pluronic gel concentration on the PNS 
release kinetics from four bases, namely B4, B5, B6, B8, 
and B9, were investigated. The in vitro dissolution profile 
of the PNS in gels is shown in Figure 5. It is clear from this International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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figure that the addition of MC was able to retard the release 
of progesterone after 10 h. B6 and B9 that contained pluronic 
F127 (25% and 30% w/v) plus MC released only 44% and 
40% of the added PNS, respectively, while B5 and B8 gel 
contained pluronic F127 (25% and 30% w/v) plus HPMC 
released only 65% and 55% of the added PNS, respectively. 
The release kinetics of the drug from the four series followed 
a zero order of kinetics. However, the release of the drug from 
B4 (the 25% w/v pluronic) gel was found to be controlled 
by diffusion (Figure 5).
There was a high correlation between the percentage 
weight of dissolved gel with the cumulative percentage drug 
release in most of the studied series except in B5 which con-
tained the mixture of 25% pluronic gel and HPMC (Figure 6a 
and 6b). This indicates that the overall rate of the drug release 
into the dissolution medium was controlled by the dissolution 
of the gel. However, the involvement of other mechanisms, 
including diffusion of the drug through extramicellar aqueous 
channels, degradation of the gel matrix, or diffusion out of 
the nanosuspended particles, cannot be excluded.21,22,30 The 
25% pluronic gel with the MC base (B6) was shown to have 
the highest correlation between cumulative drug release with 
percentage weight of dissolved gel (r2 . 0.99). In addition to 
this, this gel showed a very slow dissolution rate versus time, 
therefore it was chosen to carry out the in vivo study.
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In vivo study
In Figure 7, the pharmacokinetic parameters of the PNS 
(6 mg/mL) in pluronic F127and MC gel (B6) were evaluated 
in comparison to the control progesterone suspension. The 
results are presented as means ± standard deviation and were 
subjected to non compartmental analysis using WinNonlin 
software (version 1.5; Pharsight Corporation, St Louis, MO). 
After injection of PNS into the rats, the maximum serum con-
centration (Cmax) of 22.1 ± 1.9 ng/mL was reached at a Tmax of 
4.05 ± 0.1 h. The terminal half-life was 12.7 ± 0.8h. A higher 
progesterone plasma concentration of 37.5 ± 11.8 ng/mL was 
achieved more rapidly with the progesterone suspension in 
PBS since it was reached at a Tmax of 0.75 ± 0.0.28 h. The 
terminal half-life of the test formula was 12.7 ± 0.8 h, while 
it was 7.67 ± 3.5 h for the control. The AUC0-∞ of the test 
formula was 452.75 ± 42.8 ng·h/mL and the total mean resi-
dence time (MRT) was 18.57 ± 1.44 h. On the other hand, the 
AUC0-∞ of the control was 206.7 ± 21.9 and the total MRT was 
10.2 ± 1.7 h. Applying t-test for non paired data, the results 
of PNS were significantly different at P , 0.001.
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Figure 7 Pharmacokinetic profile of progesterone nanosuspension in F127 (25% 
w/v) with Mc (1% w/v) () and progesterone powder in PBS () in ovariectomized 
female rats.
The previous results showing that poloxamer vehicle 
resulted in prolongation of plasma concentrations of PNS, 
which was detected from the ratio between the MRT of the 
test formula to the MRT of the control, was found to be equal 
to 1.8. The Tmax for progesterone in pluronic test base carrying 
PNS (test) was four times slower than that of the control. In 
the case of PNS embedded into the thermosensitive base, a 
more uniform plasma profile was detected (Figure 7). This 
effect may be a result of the uniform distribution of PNS in 
the hydrophilic matrix. At the same time, a slower elimina-
tion rate may have had an additional effect in prolonging the 
effect of the pluronic base.22 The relative bioavailability of 
the test formula to the control was almost 210%, which was 
found to be significant at P , (0.001).
It is clear from the results that the pluronic gel was suc-
cessful in modulating the release of progesterone in plasma 
since it was able to sustain the progesterone level over 36 h 
to achieve its therapeutic effect. There was a limited fluctua-
tion in progesterone levels in the blood when the pluronic 
gel was used which could be predicted from the very narrow 
standard deviation. This can give an additional advantage for 
using the gel over using the control.
The therapeutically effective concentration of progesterone 
was reported to be 2–5 ng/mL in plasma of some animals.26,38 
In this work, the lowest level of exogenous progesterone is 
approaching 5 ng/ml. This level is in agreement with what 
was reported in the literature about the pharmacokinetics of 
progesterone. Mannino et al, reported about a subcutaneous 
implant that contained 40 mg of progesterone in ovariectomized 
rats.39 The peak serum progesterone was 21 ± 1.6 ng/mL and the 
lowest serum level was 6.9 ± 0.6 ng/mL. In the present study, 
we formulated PNS in F127 gel using only 6 mg of proges-
terone and achieved the same level, but for a shorter duration. 
It is clear that the gel offers advantages of injectability unlike 
the implants, which require surgical operations. The gel is International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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injectable at 4°C and has a shear thinning pseudoplastic flow, 
which facilitates its administration to patients.37 Achieving 
physiological levels of progesterone is a vital requirement to 
prevent any embryonic loss in oocyte retrieval operations.40 
Administration of supranormal levels of progesterone during 
early pregnancy caused reduction in the number of implantation 
and an increase in the preimplantation loss in mice.41 Therefore, 
achieving low level of progesterone such as the level achieved 
by the present work, it could be advantageous in bringing the 
normal progesterone level and keeping the embryo safe.
However, the optimum dose required from progesterone 
cannot be determined because it depends on the initial level 
of endogenous progesterone and the level needed to keep the 
pregnancy. There are inconsistencies in the studies describ-
ing the required levels of progesterone for maintaining the 
pregnancy. In a study reported by Pepe and Rothchild, who 
measured the level of progesterone in pseudopregnant rats, 
found progesterone level to be 70 ng/mL on day five of 
pregnancy and reaching 120 ng/mL on day 11.42 The same 
group found that pregnancy can be maintained at level of 
progesterone 75%–80% lower than the normal value.43
In humans, pregnancy outcomes can be predicted from 
serum progesterone levels which ranged from 12.3–80.9 ng/mL 
for pregnant women and from 8.4–18.2 ng/mL in non pregnant 
women.44 Keeping a steady level of progesterone during early 
pregnancy is indicated. The present formula offers delivery of 
progesterone for an extended period of time to be given every 
36 h instead of every 24 h. Progesterone in the present formula 
is suspended in hydrophilic base which may provide a more 
convenient alternative than oil bases provided in market. This 
may offer a new application of our formula in future. However, 
a higher concentration of PNS may be needed to provide a 
higher input of progesterone in plasma.45
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